They are the per-dose amounts published on this sites own protocol pages for each vial size, which is the reference this guide is built to explain and make arithmetically checkable
In the LEAD-5 trial, liraglutide (1.8 mg once daily) reduced HbA1c more than insulin glargine during the treatment period (26 weeks) [31]
The renal effects of arGLP1 in patients with CKD have been evaluated in other studies
At present, even though the comparative efficacy of tirzepatide vs these higher dosing regimens of dulaglutide and semaglutide is unknown, available data suggest that tirzepatide could be a reasonable treatment option when glycaemic control and body weight loss are therapeutic priorities
What started as a treatment for type 2 diabetes has rapidly evolved into a platform therapy influencing obesity, cardiovascular disease, fatty liver disease, neurodegeneration, inflammation, and potentially oncology
PMC 1828602